Share This Link

Changing to ofloxacin is incorrect. Ofloxacin is also a fluoroquinolone, and this class of medications is associated with an increased risk of tendonitis and tendon rupture. Switching to another drug in the same class would not eliminate the risk and could worsen the condition.

Changing to ciprofloxacin is incorrect. Ciprofloxacin is another fluoroquinolone and carries the same boxed warning for tendon injury. Substituting one fluoroquinolone for another does not address the underlying adverse effect.

Reassuring the patient that this is a common side effect is incorrect. Tendon pain is not a benign or expected side effect—it is a warning sign of a potentially serious complication requiring prompt intervention.

TMP/SMX should not be prescribed for children younger than 2 years is incorrect. The medication is contraindicated in infants younger than 2 months, not 2 years, due to the risk of kernicterus.

Folic acid supplements must be given to children who take this medication is incorrect. While trimethoprim can interfere with folic acid metabolism, routine supplementation is not typically required unless the child has a deficiency or is on prolonged therapy.

The medication should be given three or four times per day because of rapid metabolism is incorrect. TMP/SMX is usually administered twice daily, not three or four times per day, due to its pharmacokinetics.

Pyrimethamine (Daraprim) is incorrect. It is not recommended as a single agent for prevention or routine treatment of malaria due to widespread resistance. Although it may be used in combination with other drugs in specific situations, it is not appropriate for travelers needing reliable prophylaxis and treatment in chloroquine-resistant areas.

Artemisinin is incorrect. Artemisinin-based therapies are highly effective for treating malaria, particularly Plasmodium falciparum, but they are not used for prevention. Their short half-life requires combination with other agents, making them unsuitable for prophylaxis.

Melarsoprol is incorrect. This medication is used to treat late-stage African trypanosomiasis (sleeping sickness) and is highly toxic. It has no role in the prevention or treatment of malaria.

Ordering liver function tests (LFTs) is incorrect. Although some antibiotics are hepatically metabolized and require monitoring of liver enzymes, cefdinir is not primarily processed by the liver. Hepatic impairment does not significantly affect cefdinir clearance, so baseline LFTs are not routinely necessary before starting this medication.

Ordering coagulation studies is incorrect. While certain cephalosporins (especially those with an NMTT side chain) can interfere with vitamin K–dependent clotting factors and increase bleeding risk, cefdinir does not commonly cause this effect. Therefore, baseline coagulation testing is not indicated unless the patient has another condition that warrants it.

Ordering an EKG is incorrect. Cefdinir is not associated with cardiac conduction abnormalities, such as QT interval prolongation, and does not pose a known risk for arrhythmias. Therefore, cardiac monitoring is unnecessary prior to initiating therapy.

Clindamycin is effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which is a common cause of skin abscesses. It does not carry a risk of tendon rupture, making it suitable for athletes. Common side effects include gastrointestinal upset and risk of Clostridioides difficile infection, but these risks are manageable.

Doxycycline is another option for treating MRSA-related skin infections. It is well-tolerated and does not increase the risk of tendon injury. Athletes can safely take doxycycline if indicated. It can cause photosensitivity, so patients should be advised to use sun protection.

TMP-SMX is effective against community-acquired MRSA and commonly used for outpatient management of skin abscesses. It does not increase the risk of tendon injury, making it safe for a marathon runner. Adverse effects may include rash, gastrointestinal upset, and rarely hematologic effects, which should be monitored.

Penicillin G is a beta-lactam antibiotic. Beta-lactams generally do not have a significant post-antibiotic effect, meaning their bactericidal activity is closely related to the time the drug concentration remains above the MIC. Therefore, penicillin requires frequent dosing (usually every 4–6 hours) to maintain effective antibacterial activity.

Vancomycin, a glycopeptide antibiotic, does not exhibit a significant post-antibiotic effect against most Gram-positive bacteria. Its dosing is time-dependent, and therapeutic levels must be maintained to ensure effectiveness. Dosing is typically every 8–12 hours, adjusted for renal function.

Aztreonam, a monobactam antibiotic, is primarily time-dependent and does not exhibit a prolonged post-antibiotic effect. Effective therapy requires maintaining concentrations above the MIC for a significant portion of the dosing interval, necessitating frequent administration rather than once-daily dosing.

Ciprofloxacin is a fluoroquinolone. Fluoroquinolones are generally contraindicated during pregnancy, especially in the first trimester, because they can affect fetal cartilage development and potentially cause musculoskeletal abnormalities. They are reserved for situations where no safer alternatives are available.

Doxycycline, a tetracycline, is contraindicated in pregnancy because it can cause fetal tooth discoloration and inhibition of bone growth, especially if used during the second or third trimester. It is also avoided in the first trimester due to risk of developmental toxicity.

TMP-SMX should generally be avoided in the first trimester because trimethoprim is a folate antagonist and may increase the risk of neural tube defects. Additionally, sulfonamides in late pregnancy can increase the risk of kernicterus in the newborn.

CDC guidelines provide standardized recommendations for infection management, vaccination, and antimicrobial use, but they are not the same as an antibiogram. An antibiogram is a lab-generated tool reflecting local bacterial susceptibility patterns, not national guidance.

While clinical algorithms can guide antibiotic selection, an antibiogram is not an algorithm. It does not provide step-by-step treatment instructions but shows actual susceptibility data for local bacterial isolates.

The Pink Book is a CDC publication titled “Epidemiology and Prevention of Vaccine-Preventable Diseases”. It relates to vaccines, not antibiotics or bacterial resistance.

Clarithromycin is extensively metabolized by the liver. In patients with hepatic impairment, the drug can accumulate, increasing the risk of hepatotoxicity and prolonged QT interval. Dose adjustments are required for significant liver dysfunction, and careful monitoring is necessary. Because this patient already has chronic hepatitis, clarithromycin is less safe compared with azithromycin.

Erythromycin is also heavily metabolized by the liver, primarily via the cytochrome P450 system, which makes it prone to drug interactions and hepatotoxicity in patients with liver disease. Gastrointestinal side effects, such as nausea and diarrhea, are also more common with erythromycin, and it is generally not preferred for patients with liver impairment.

This is incorrect because azithromycin is suitable and safe for patients with mild hepatic impairment. Choosing “none of the above” would unnecessarily exclude an effective and safe option.

Tendon rupture is associated with fluoroquinolones, not tetracyclines. Tetracyclines do not carry a significant risk of tendon injury.

Some tetracyclines, such as minocycline, do penetrate the CSF to a limited extent, but this is not the reason for avoidance in young children. CSF penetration is related to infection treatment, not pediatric safety.

Aplastic anemia is a rare adverse effect associated with some drugs (e.g., chloramphenicol), but it is not a major concern with tetracyclines. The primary pediatric concern is tooth and bone deposition.